The global pancreatic cancer treatment market size was estimated to be USD 2.87 billion in 2023 and is expected to reach at USD 14.45 billion by 2034 with a CAGR of 15.83% during the forecast period 2024-2034. Growing prevalence of pancreatic cancer, rising geriatric population, surge in the number of patients suffering from the condition, increasing demand for novel drugs, growing approvals by regulatory authorities, new testing technologies are being adopted by hospitals and diagnostic centers to diagnose cancer, and surge in research & development activities to develop new drugs for pancreatic cancer treatment are a few of the main elements fuelling the market's expansion.
Surge in research & development activities to develop new drugs for pancreatic cancer treatment is predicted to boost the market growth during the forecast period. Pancreatic cancer is often not detected in its early stages, which are more treatable, as it typically does not exhibit symptoms until it has advanced to other organs. The severity of the disease influences the available treatment options for pancreatic cancer, including surgery, chemotherapy, radiation therapy, or a combination of these interventions. Therefore, market players are directing their efforts towards the development of innovative treatments for pancreatic cancer. For instance, in March 2023, Novartis is presently in Phase I of clinical development for LGK-974 targeting metastatic pancreatic cancer. The benchmark for the Phase I to Phase II transition success rate (PTSR) for drugs in Phase I targeting Metastatic Pancreatic Cancer is reported to be 88%, according to GlobalData.
By type, exocrine was the highest revenue-grossing segment in the global pancreatic cancer treatment market in 2023 owing to the rising prevalence of exocrine cancer, surge in diagnosis rate of exocrine pancreatic cancer, and growing collaborations within market players. For instance, in October 2022, Erasca, a California-based company, has extended its existing partnership with Pfizer to evaluate ERAS-007 in combination with Pfizer's Ibrance (palbociclib). The extended collaboration involves a clinical trial collaboration and supply agreement, paving the way for both biopharmaceutical companies to conduct a clinical proof-of-concept study. Additionally, endocrine is predicted to grow at fastest CAGR during the forecast period owing to the rise in the adoption of advanced technologies, heightened awareness among consumers about pancreatic endocrine tumors, a growing geriatric population, and an increase in the number of patients afflicted with pancreatic neuroendocrine tumors contribute to the evolving landscape of this medical condition.,
By treatment, chemotherapy was the highest revenue-grossing segment in the global pancreatic cancer treatment market in 2023 owing to the growing adoption as the primary treatment option for many individuals diagnosed with this type of cancer and increasing approvals by regulatory authorities. For instance, in May 2023, Alligator Bioscience has announced that the FDA has granted an orphan drug designation (ODD) to mitazalimab for the treatment of patients with pancreatic cancer. Additionally, radiation therapy is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of advanced technologies within hospitals & clinics for treating cancer patients has resulted in the increased utilization of advanced radiation therapy equipment.
By end-user, hospitals was the highest revenue-grossing segment in the global pancreatic cancer treatment market in 2023 owing to the rising adoption as primary care, increase in number of patients taking chemotherapy, radiation therapy, & other treatments at hospitals, surge in adoption of new technologies by hospitals for the diagnosis and treatment of this condition, and growing regulatory approvals. For instance, in January 2022, The U.S. Food and Drug Administration (FDA) has granted orphan drug status for Multitargeted T-cell therapy in the treatment of pancreatic cancer. This treatment, when combined with chemotherapy, holds the potential to generate enduring effects in individuals with advanced or metastatic pancreatic cancer. Additionally, clinics is predicted to grow at fastest CAGR during the forecast period owing to the increase in the number of cancer patients visiting clinics for treatment, growth in the number of clinics offering chemotherapy and radiation treatment, as well as a rise in the privatization of clinic construction.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of advanced healthcare facilities, the growing adoption of new diagnostic technologies, an increase in the prevalence of the condition, heightened research and development investments by major industry players, favorable government regulations, an upsurge in government-launched awareness programs, and increasing partnerships & collaborations among market players. For instance, in January 2022, AstraZeneca has entered into a collaboration with Scorpion Therapeutics to jointly discover, develop, and commercialize precision medicines targeting cancer proteins that were previously challenging to target. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of cancer, advancements in healthcare infrastructure, a rise in the number of pharmaceutical companies developing products for the treatment of pancreatic cancer, a growing geriatric population, and surge in collaborations within market players. For instance, in August 2022, Apollo Proton Cancer Centre (APCC) in India has signed an agreement with Ion Beam Applications (IBA) in Belgium to offer training for clinicians in proton-based radiation therapy.
Surge in research & development activities to develop new drugs for pancreatic cancer treatment is predicted to boost the market growth during the forecast period. Pancreatic cancer is often not detected in its early stages, which are more treatable, as it typically does not exhibit symptoms until it has advanced to other organs. The severity of the disease influences the available treatment options for pancreatic cancer, including surgery, chemotherapy, radiation therapy, or a combination of these interventions. Therefore, market players are directing their efforts towards the development of innovative treatments for pancreatic cancer. For instance, in March 2023, Novartis is presently in Phase I of clinical development for LGK-974 targeting metastatic pancreatic cancer. The benchmark for the Phase I to Phase II transition success rate (PTSR) for drugs in Phase I targeting Metastatic Pancreatic Cancer is reported to be 88%, according to GlobalData.
By type, exocrine was the highest revenue-grossing segment in the global pancreatic cancer treatment market in 2023 owing to the rising prevalence of exocrine cancer, surge in diagnosis rate of exocrine pancreatic cancer, and growing collaborations within market players. For instance, in October 2022, Erasca, a California-based company, has extended its existing partnership with Pfizer to evaluate ERAS-007 in combination with Pfizer's Ibrance (palbociclib). The extended collaboration involves a clinical trial collaboration and supply agreement, paving the way for both biopharmaceutical companies to conduct a clinical proof-of-concept study. Additionally, endocrine is predicted to grow at fastest CAGR during the forecast period owing to the rise in the adoption of advanced technologies, heightened awareness among consumers about pancreatic endocrine tumors, a growing geriatric population, and an increase in the number of patients afflicted with pancreatic neuroendocrine tumors contribute to the evolving landscape of this medical condition.,
By treatment, chemotherapy was the highest revenue-grossing segment in the global pancreatic cancer treatment market in 2023 owing to the growing adoption as the primary treatment option for many individuals diagnosed with this type of cancer and increasing approvals by regulatory authorities. For instance, in May 2023, Alligator Bioscience has announced that the FDA has granted an orphan drug designation (ODD) to mitazalimab for the treatment of patients with pancreatic cancer. Additionally, radiation therapy is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of advanced technologies within hospitals & clinics for treating cancer patients has resulted in the increased utilization of advanced radiation therapy equipment.
By end-user, hospitals was the highest revenue-grossing segment in the global pancreatic cancer treatment market in 2023 owing to the rising adoption as primary care, increase in number of patients taking chemotherapy, radiation therapy, & other treatments at hospitals, surge in adoption of new technologies by hospitals for the diagnosis and treatment of this condition, and growing regulatory approvals. For instance, in January 2022, The U.S. Food and Drug Administration (FDA) has granted orphan drug status for Multitargeted T-cell therapy in the treatment of pancreatic cancer. This treatment, when combined with chemotherapy, holds the potential to generate enduring effects in individuals with advanced or metastatic pancreatic cancer. Additionally, clinics is predicted to grow at fastest CAGR during the forecast period owing to the increase in the number of cancer patients visiting clinics for treatment, growth in the number of clinics offering chemotherapy and radiation treatment, as well as a rise in the privatization of clinic construction.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of advanced healthcare facilities, the growing adoption of new diagnostic technologies, an increase in the prevalence of the condition, heightened research and development investments by major industry players, favorable government regulations, an upsurge in government-launched awareness programs, and increasing partnerships & collaborations among market players. For instance, in January 2022, AstraZeneca has entered into a collaboration with Scorpion Therapeutics to jointly discover, develop, and commercialize precision medicines targeting cancer proteins that were previously challenging to target. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of cancer, advancements in healthcare infrastructure, a rise in the number of pharmaceutical companies developing products for the treatment of pancreatic cancer, a growing geriatric population, and surge in collaborations within market players. For instance, in August 2022, Apollo Proton Cancer Centre (APCC) in India has signed an agreement with Ion Beam Applications (IBA) in Belgium to offer training for clinicians in proton-based radiation therapy.
Segmentation: Pancreatic Cancer Treatment Market Report 2023 - 2034
Pancreatic Cancer Treatment Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Endocrine
- Exocrine
Pancreatic Cancer Treatment Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- Radiation Therapy
- Chemotherapy
- Others
Pancreatic Cancer Treatment Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Clinics
- Others
Pancreatic Cancer Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Pancreatic Cancer Treatment Market: Type Estimates & Trend Analysis
8. Pancreatic Cancer Treatment Market: Treatment Estimates & Trend Analysis
9. Pancreatic Cancer Treatment Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Pancreatic Cancer Treatment Market
12. Europe Global Pancreatic Cancer Treatment Market
13. Asia Pacific Global Pancreatic Cancer Treatment Market
14. Latin America Global Pancreatic Cancer Treatment Market
15. MEA Global Pancreatic Cancer Treatment Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Genentech (F. Hoffmann-La Roche Ltd)
- Oncolytics Biotech Inc.
- Bristol-Myers Squibb Company
- AstraZeneca
- Novartis AG
- Ipsen Pharma
- Clovis Oncology Inc.
- Pfizer Inc.
- TME Pharma
- Erytech Pharma
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.87 Billion |
| Forecasted Market Value ( USD | $ 14.45 Billion |
| Compound Annual Growth Rate | 15.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
